231 related articles for article (PubMed ID: 33455475)
1. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
2. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in refractory pemphigus vulgaris.
Sorce M; Aricò M; Bongiorno MR
Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
7. Iranian guideline for rituximab therapy in pemphigus patients.
Daneshpazhooh M; Balighi K; Mahmoudi H; Tavakolpour S; Abedini R; Soori T; Ehsani AH; Ghiasi M; Noormohammadpour P; Ghandi N; Lajevardi V; Sadeghinia A; Nasimi M; Azizpour A; Chams-Davatchi C
Dermatol Ther; 2019 Sep; 32(5):e13016. PubMed ID: 31269316
[TBL] [Abstract][Full Text] [Related]
8. Current biologics in treatment of pemphigus foliaceus: a systematic review.
Carver CA; Kalesinskas M; Ahmed AR
Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
[TBL] [Abstract][Full Text] [Related]
9. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
Ahmed AR; Shetty S
Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
12. Clinical resolution of pemphigus vulgaris on rituximab.
Cusick E; Silverstein D
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469734
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E
Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541
[TBL] [Abstract][Full Text] [Related]
15. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
[TBL] [Abstract][Full Text] [Related]
16. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
Brown AE; Motaparthi K; Hsu S
Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
18. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
Maho-Vaillant M; Perals C; Golinski ML; Hébert V; Caillot F; Mignard C; Riou G; Petit M; Viguier M; Hertl M; Boyer O; Calbo S; Fazilleau N; Joly P
J Invest Dermatol; 2021 Sep; 141(9):2132-2140.e1. PubMed ID: 33766510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]